Immune Checkpoint Inhibition in Lung Cancer: The Good, the Bad, and the Ugly.

Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.